http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2217112-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N2-00 |
| filingDate | 2001-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2003-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e56f6a832d0debae37979715108bc663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c69ee19bd203811e547e5cdd52c8182a |
| publicationDate | 2003-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2217112-C2 |
| titleOfInvention | Method for treating central chorioretinal dystrophy (ccrd) |
| abstract | FIELD: medicine, ophthalmology. SUBSTANCE: catheter should be introduced into retrobulbar space. Heparin, emoxypin, dicynon and riboflavin should be injected in two stages in 6 h. Between stages an impact is performed onto pathological focus for 10 min with impulse alternating magnetic field at 12 mTl induction, 50 Hz frequency, 3 min impulse discreteness. At treating dry forms of CCRD one should stimulate macular area for 3 min before injection of any preparations with radiation of low-intensity He-Ne laser at 0.63 nm wave length, and trental should be added to preparations injected. At treating humid forms of CCRD dexason should be added to preparations injected. The method enables to stabilize rheological blood properties, increase permeability of membranes for medicinal preparations injected, enhance metabolic processes, activate pigmentary retinal epithelium. EFFECT: higher efficiency of therapy. 2 cl, 3 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2527154-C1 |
| priorityDate | 2001-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.